Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16566390 | 0.84 | SMYD3 (0.57) | SMYD3BAZ2BUSP30MAP3K5KLKB1 | |
| SCHEMBL4891287 | 0.79 | MEN1 (0.44) | SMYD3 | |
| SCHEMBL4901656 | 0.78 | PLA2G4A (0.39) | SMYD3USP30 | |
| SCHEMBL19017622 | 0.78 | USP30 (0.55) | SMYD3BAZ2BUSP30BRD4CNR1 | |
| SCHEMBL28726420 | 0.77 | ADA (0.42) | SMYD3USP30 | |
| SCHEMBL18377475 | 0.76 | KLKB1 (0.56) | USP30KLKB1BRD4 | |
| SCHEMBL1662858 | 0.74 | BAZ2B (0.46) | SMYD3BAZ2BBRD4CNR1 | |
| SCHEMBL9714265 | 0.73 | RIPK1 (0.42) | SMYD3KLKB1 | |
| SCHEMBL19980440 | 0.71 | SMYD3 (0.40) | SMYD3BAZ2BUSP30KLKB1BRD4 | |
| SCHEMBL16543478 | 0.70 | BAZ2B (0.39) | SMYD3BAZ2BBRD4CNR1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1894206-A | N-substituted N-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2007-01-10 | — | — | CN | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | SMYD3 921/4885BAZ2B 1755/4885USP30 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.